Scholars Central

ArticlePublished 18 Jan 2024

Clinical Efficacy of Chemotherapy Combined with Vascular Targeted Agents in Advanced Liver Cancer Treatment

Authors: H. Dai, Yinyun Zheng, Jiane Wang, Peifeng Zhu

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

This study aims to assess the clinical efficacy of combining chemotherapy with vascular targeted agents in managing advanced liver cancer. A total of 86 patients diagnosed with advanced liver cancer between March 2020 and August 2022 were enrolled in this study. They were randomly divided into an observation group (n=43) receiving chemotherapy combined with vascular targeted agents and a control group (n=43) receiving chemotherapy alone. The study compared treatment outcomes, tumor marker levels, inflammatory cytokine profiles, quality of life, and adverse reactions between the two groups. Prior to treatment, no significant differences were observed in the levels of alpha-fetoprotein, vascular endothelial growth factor, fibroblast growth factor, and carcinoembryonic antigen between the observation and control groups (p>0.05). Post-treatment, the observation group exhibited significantly lower alpha-fetoprotein, vascular endothelial growth factor, fibroblast growth factor, and carcinoembryonic antigen levels compared to the control group (p 0.05). Post-treatment, interleukin-6 and tumor necrosis factor-alpha levels decreased in the observation group, while interleukin-10 levels increased in comparison to the control group (p 0.05). However, post-treatment, the observation group showed higher quality of life scores than the control group (p 0.05). Combining chemotherapy with vascular targeted agents for treating advanced liver cancer is associated with notable reductions in tumor marker levels, modulation of immune function, and enhanced patient quality of life. This combined approach is both safe and reliable, warranting its consideration for wider clinical application and promotion.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Indian Journal of Pharmaceutical Sciences.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalIndian Journal of Pharmaceutical Sciences
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “H. Dai”
  • BylineArticles whose byline prints “Yinyun Zheng”
  • BylineArticles whose byline prints “Jiane Wang”
  • BylineArticles whose byline prints “Peifeng Zhu”